undamentalytics Newsletter
Sign in

Korro Bio, Inc. cash flow statement

In fiscal 2025, Korro Bio, Inc.'s operations generated −$78.6m of cash; it spent $518,000 on capital projects, leaving free cash flow of −$79.1m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations34−45−76−54−67−60−79−68
Depreciation and amortisation11334443
Stock-based pay41022202489
Capital spending173581810
Free cash flow33−52−79−59−75−78−79−68
Free cash flow after stock pay30−62−101−79−78−82−87−78
Shares issued802101170——

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CLGN vs KRROKRRO vs VTGNKRRO vs KRSA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Korro Bio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Korro Bio, Inc.